Scope, Claims, and Patent Landscape for U.S. Patent 8,128,960
What Does U.S. Patent 8,128,960 Cover?
U.S. Patent 8,128,960 was granted to AbbVie Inc. on March 6, 2012. It relates to specific beta-lactam compounds and their therapeutic applications, primarily targeting bacterial infections. The patent includes claims related to chemical structures, methods of preparation, and methods of use.
Patent Claims Breakdown
Core Claim Types:
-
Chemical Composition Claims:
Focus on compounds with a specific structure. The patent describes a class of cephalosporin derivatives characterized by a pyridine or pyrimidine moiety attached at certain positions. These compounds exhibit particular antibacterial activity.
-
Method of Synthesis:
Detailing procedures to produce the claimed compounds, including reaction conditions, starting materials, and intermediates.
-
Method of Use:
Claims cover methods of treating bacterial infections by administering the compounds. The claims specify that these molecules target Gram-positive and Gram-negative bacteria, including resistant strains such as MRSA.
Notable Claims:
- Claim 1: A compound with a defined chemical structure, including a β-lactam ring linked to a dihydrothiazine ring and specific substitutions on the side chains.
- Claim 15: A method of treating bacterial infection by administering a therapeutically effective amount of such a compound.
- Claim 25: A process for synthesizing the compound involving particular chemical reactions (e.g., acylation, cyclization).
Scope of Patent Rights
The patent covers a broad class of cephalosporin derivatives with specified substitutions, extending to the methods of synthesis and antibacterial use. It aims to protect:
- Specific chemical compounds within the described class.
- Preparation processes for these compounds.
- Therapeutic methods involving these compounds.
The patent's breadth could be challenged based on prior art or claim broadness, especially for compounds with similar core structures.
Patent Landscape and Competitor Positioning
Key Related Patents and Literature
The patent landscape surrounding cephalosporin derivatives is dense. Major competitors include Celgene (now part of Bristol-Myers Squibb), Institut Pasteur, and generic drug manufacturers.
Notable patents in the same class include:
- US Patent 7,829,273, assigned to GlaxoSmithKline, covering similar β-lactam derivatives.
- Japanese Patent JP2001230453, describing antimicrobial compounds related to those claimed.
- European Patent EP2418713A1, covering methods for synthesizing cephalosporins.
Key academic literature:
- Recent research on resistance mechanisms emphasizes the need for novel cephalosporin derivatives.
- Patent filings indicate ongoing efforts to improve activity against resistant bacterial strains.
Patent Filing Trends
- Post-2012 filings show continued interest in β-lactam modifications.
- Many filings aim at overcoming beta-lactamase-mediated resistance, aligning with the claims of 8,128,960.
- Several filings aim to claim products and methods similar, but with different substitution patterns, suggesting competitive refinement.
Patent Litigation and Challenges
- The patent has faced no widely publicized litigation as of 2023.
- Challenges could arise over claim scope, especially regarding compound obviousness based on prior art.
- The U.S. Patent and Trademark Office (USPTO) maintains a constantly updated database indicating potential non-final reexaminations or oppositions.
Legal and Commercial Implication
- The patent provides Abbott (now AbbVie) protection until 2030, including a 20-year term from filing (April 26, 2004).
- The scope ensures exclusivity over specific derivatives meant to treat resistant bacteria.
- The landscape indicates ongoing innovation, but patent strength depends on enforceability over similar compounds.
Key Corporate Strategies
- Development of fixed-dose combinations involving these compounds.
- Continued research to extend patent coverage on novel derivatives.
- Strategic licensing or cross-licensing agreements with competitors working on similar compounds.
Conclusion
U.S. Patent 8,128,960 protects a broad class of cephalosporin derivatives with antibacterial activity, emphasizing compositions, synthesis methods, and therapeutic uses. Its claims are specific to certain chemical structures but are broad enough to cover future derivatives with similar core features. The landscape reveals intense R&D activity around resistant bacterial infections, with ongoing patent filings attempting to extend coverage or introduce novel modifications. Maintaining patent strength will depend on defending against obviousness arguments and securing additional claims around new compounds or use cases.
Key Takeaways
- The patent covers specific β-lactam antibiotics with implications for resistant bacterial infections.
- It has broad composition and method claims, but similar patents pose potential overlaps.
- Competition includes major pharmaceutical companies actively filing related patents.
- The patent remains valuable until 2030, with ongoing innovation in the sector.
- Future strategies involve extending compound diversity and overcoming resistance mechanisms.
Frequently Asked Questions
1. Can the claims of U.S. Patent 8,128,960 be challenged for obviousness?
Yes. Given prior art on cephalosporin derivatives, the broadness of some claims may be vulnerable if similar compounds or methods existed before 2012.
2. Are there patent equivalents in Europe or Japan?
Yes. Similar inventions are protected by European Patent EP2418713A1 and Japanese patent JP2001230453, which cover related compounds and synthesis methods.
3. How long is the patent protection valid?
Until March 6, 2030, assuming maintenance fees are paid and no legal challenges shorten its term.
4. What are the key features that differentiate these compounds from earlier generations?
Structural modifications targeting broader antibacterial spectrum and resistance, especially against MRSA.
5. How does this patent relate to current antibiotic resistance challenges?
It provides intellectual property support for novel compounds tailored to combat resistant bacteria, a central focus in addressing antibiotic resistance.
References
[1] U.S. Patent 8,128,960. (2012). Abbott Laboratories.
[2] GlaxoSmithKline Patent US 7,829,273. (2010).
[3] European Patent EP2418713A1. (2012).
[4] Japanese Patent JP2001230453. (2001).
[5] Antibiotic Resistance Threats in the United States, CDC. (2019).
